Cancer treatment is on the verge of a major change. Intratumoral immunotherapy is leading the way, offering new hope to those fighting cancer. This method targets tumors directly, waking up the body’s immune system to fight cancer from within.
This treatment approach provides a time and spatial approach simultaneously. It attacks cancer cells directly and acutely, and boosts the immune system to provide a systemic and sustained anti-tumor immune response. This means fewer side effects and better results, in the short and long term, for those facing tough cancer battles.
Doctors can now tailor treatments to each patient’s cancer. This personalized approach, the right treatment for the right patient at the right time, is a big step forward in cancer care. It promises more effective and less toxic treatments.
Let’s dive into the world of intratumoral immunotherapy. We’ll look at how it works, its benefits, and the hope it offers to cancer patients everywhere. Get ready to see how this cutting-edge treatment is changing cancer care.
What Is Intratumoral Immunotherapy?
Intratumoral immunotherapy is a new way to fight cancer. It targets tumors and cancer cells directly. This method is getting a lot of attention in the medical world.
Direct Tumor Targeting: How Intratumoral Immunotherapy is Redefining Cancer Treatment & Remission
Understanding Localized Cancer Treatment
Localized cancer treatment focuses and targets specific tumors. It limits negative effects in the whole body. Off-target toxicity prominent in the systemic-to-tumor approach is minimized in this tumor-to-systemic approach. Intratumoral immunotherapy involves injecting drugs directly into tumors. This helps the body’s immune system do what it does best–fight cancer cells.
The intratumoral approach to cancer therapy avoids the war mentality of the systemic-to-tumor approach which has turned many an individual’s body into a battlefield. Instead, the intratumoral approach de-escalates the war away from the body solely to target the tumor and activates the immune system to take the targeted effects to distant untreated tumors. It overcomes the many limitations of the systemic approach. The image below highlights the impact and benefit of the intratumoral approach.
Intratumoral ablation and immunotherapy work together to enhance treatment effectiveness, targeting tumors both locally and systemically.
How Intratumoral Therapy Activates the Immune System
Intratumoral therapy starts a local immune response in the tumor. When therapeutics are injected, they trigger the immune system to attack the cancer locally and acutely. This can destroy cancer cells within the tumor and release new specific antigens called neoantigens. The creation of these neoantigens sets the stage for immune system activation.
Intratumoral Immunotherapy
There are many therapeutic options that can be used to activate the immune system via the intratumoral delivery route. The following are a few examples of the multiple classes of intratumoral immunotherapies under development and investigation in preclinical and clinical studies:
- Cytokines
- Monoclonal antibodies
- Natural therapies
- Integrative therapies
- Immune cell-based therapies
- Nucleic acid sequences
- Patter Recognition Receptor Agonists
- Viral and nonviral oncolytic immunotherapies
The Difference Between Local and Systemic Effects
Intratumoral therapy has both local and systemic effects. It starts locally, harnessing the power of the immune system, trains the immune system, activates the immune system, then transfers the activated immune system to target distant untreated tumors. Here’s how it compares to other treatments:
| Local Effects | Systemic Effects |
| Direct tumor cell death | Immune recognition (memory) of cancer cells throughout the body |
| Changes in tumor microenvironment | Potential impact on distant metastases |
| Immediate immune cell recruitment | Long-term memory immune response |
Intratumoral immunotherapy is a promising cancer treatment. It combines local treatment with a systemic immune response. This offers a unique way to fight cancer.
The Tumor Microenvironment (TME) and Its Challenges
The tumor immune microenvironment (TIME) is vital in cancer growth. It’s crucial to understand this complex system for effective treatments.
What Is the Tumor Microenvironment?
The TME is the area around cancer cells. A tumor can no longer be thought of as a solid ball of cancer cells isolated from the rest of the body. The TME is the zone where cancer cells and normal cells coexist. It includes cancer cells, endothelial cells, immune cells, cytokines, growth factors, cancer associated fibroblasts, adipocytes, stellate cells, extracellular matrix, and free fatty acids. This TME environment often helps tumors grow and avoid detection by the immune system-immunoevasion.
How the Tumor Immune Microenvironment (TIME) Suppresses Immune Responses
Cancer cells within the TIME can trick the immune system. They send signals that stop immune cells from working right. Moreover, they take advantage of immune system mechanisms that keep the immune system from attacking the body, called immune check points. This process, called immunosuppression, doesn’t just reduce the number of immune cells, but can disable the immune cells and make it harder for the body’s immune system to recognize and fight cancer on its own.
| Immunosuppressive Factors | Effects on Immune System |
| Cytokines | Recruit immunosuppressive cells to the TME |
| PD-L1 expression | Inhibits T-cell function |
| TGF-beta secretion | Suppresses immune cell activation |
| Regulatory T-cells | Dampen tumor-specific T-cell response |
| Myeloid-derived suppressor cells | Dampen tumor-specific T-cell response |
Overcoming Barriers with Intratumoral Therapies
Intratumoral therapies aim to change the tumor immune microenvironment (TIME). These treatments are given directly into the tumor. They boost immune system modulation and counter the immunosuppression created by cancer.
Immunomodulatory interventions are key in these treatments. They wake up the immune system to recognize and fight cancer through empowering the immune system not at the expense of the immune system. This immune system preservation is paradoxical to the immune system collateral damage that has dominated the war on cancer. By targeting the tumor directly, these therapies can overcome many barriers that impair the immune system from targeting cancer.
Mechanisms of Action in Intratumoral Immunotherapy
Intratumoral immunotherapy uses the body’s defenses to fight cancer. It boosts immune responses right in the tumors.
A close-up of a syringe filled with medication, poised for administration, with a blurred operating room in the background, symbolizing the precision of intratumoral immunotherapy.
Immune Checkpoint Inhibitors and Tumor Regression
Immune checkpoint inhibitors are crucial in this fight. They block the ability of immune cells to recognize and attack tumors. Immune checkpoint inhibitors unmask the cancer cells allowing T cells, Natural Killer cells, and other immune cells to identify, target, and destroy cancer cells more easily.
The Role of Cytokine Therapy in Immune Activation
Cytokine therapy involves injecting signaling molecules into tumors. These cytokines activate immune cells, recruit immune activity, direct immune cell activity, and create an anti-tumor immune environment within the pro-tumor TME characteristic in cancer. This brings more immune cells to the tumor, boosting the immune response.
Tumor-Specific Antigen Release and the Systemic Effect
When cancer cells die, they release unique markers. These markers alert the immune system to cancer locally and systemically throughout the body. This triggers a body-wide, specific, immune response, fighting tumors beyond the treatment area.
| Mechanism | Key Components | Primary Effect |
| Immune Checkpoint Inhibitors | Monoclonal antibodies | Unleash T cell activity |
| Cytokine Therapy | Interleukins, Interferons | Activate immune cells |
| Tumor Antigen Release | Cancer cell proteins | Trigger local and systemic immune response |
| Natural Killer Cell Activation | Cytokines, Antibodies | Enhance tumor cell killing |
Innovative Tools in Intratumoral Immunotherapy
Intratumoral immunotherapy is getting a boost with new tools. These tools aim to fight cancer cells directly. They help the body’s immune system attack tumors more effectively.
Oncolytic Viruses and Their Role in Tumor Destruction
Not all viruses are bad. Oncolytic virus therapies use modified viruses to target cancer cells. These viruses infect and kill tumor cells but leave healthy cells alone. As they multiply, they alert the immune system to target cancer.
Nonviral Agents and Advanced Therapeutic Options
Nonviral immunotherapy offers a unique approach. It uses innovative materials to deliver therapies directly to tumors. Beyond targeting cancer cells directly for destruction, modification of genetic expression through epigenetics can change how genes are expressed and function in cancer cells, making cancer cells easier to target for destruction.
Intratumoral Ablation Synergy with Intratumoral Immunotherapy
As powerful as intratumoral therapy alone can be, it pales in comparison to the combined synergist power of intratumoral ablation and intratumoral immunotherapy. Numerous types of tumor ablative techniques exist listed in hierarchy of most immunogenic to least immunogenic:
- Pulse-Electric Field (PEF) therapy
- Cryoablation
- Irreversible Electroporation (IRE)
- Photodynamic Therapy (PDT)
- High-Intensity Focuse Ultrasound (HIFU)
- RadioFrequency Ablation (RFA)
- Microwave Ablation (MWA)
- Laser Interstitial Thermal Therapy (LITT)
- Electrochemotherapy
Cryoablation and immunotherapy work synergistically. The rapid freezing and thawing associated with the cryoablation of tumors releases new antigens, boosting immunotherapy’s power exponentially. This synergistic combination leads to a more robust anticancer immune response.
Pulsed electric fields (PEF) in cancer is another innovative intratumoral ablative technique. PEF uses nano pulses of high voltage energy to open holes in cancer cell membranes ultimately leading to their destruction. These PEF induced openings in the cancer cells membranes make it easier for targeted therapies to enter and kill the cells, leaving healthy, non-cancer cells left unharmed.
| Treatment | Mechanism | Benefit |
| Oncolytic Viruses | Infect and kill tumor cells | Release antigens for immune activation |
| Nonviral Agents | Deliver immune-stimulating drugs | Target specific tumor areas |
| Cryoablation | Freeze/thaw cycles of tumor tissue | Release antigens, enhance immunotherapy |
| Pulsed Electric Fields | Open pores in cell membranes | Destroy cancer cells and improve drug delivery to cancer cells |
Benefits of Intratumoral Immunotherapy for Patients
Intratumoral immunotherapy is a game-changer for cancer patients. It is a paradigm shift in cancer care. It directly attacks tumors, utilizes and activates the body’s defense, immune system, improving outcomes and quality of life.
Minimizing Systemic Side Effects
This therapy targets tumors directly, unlike conventional treatments. Thought not without adverse effects, this approach significantly reduces the risk of side effects. Many of the more encountered adverse effects are note side effects, but are intended effects, i.e., low-grade fever and fatigue characteristic of immune activation. Patients often find treatment more tolerable.
Enhancing Immune System Resilience
This therapy boosts the body’s natural defenses against cancer. It trains and harnesses the power of the immune system to fight cancer cells. This could offer long-lasting protection against cancer recurrence.
Addressing Metastases Through the Abscopal Effect
Intratumoral immunotherapy has a big advantage in fighting the spread of cancer–metastasis. The abscopal effect, can target and shrink distant untreated tumors in other parts of the body. The abscopal effect was first described in 1953 by Dr. R. H. Mole. The term “abscopal” comes from the Latin “ab” (meaning “away from“) and “scopus” (meaning “target“), meaning “away from target”. This is a key part of preventing cancer from spreading.
| Benefit | Description | Impact on Patient |
| Reduced Side Effects | Minimizing systemic side effects | Improved quality of life during treatment |
| Immune Boost | Enhancing overall immune system response | Better long-term cancer control |
| Metastasis Control | Abscopal effect leading to immune-mediated tumor destruction | Potential reduction in distant, untreated tumor sites |
Intratumoral immunotherapy will change cancer treatment for the better. It offers a less invasive and more targeted way to fight cancer. As research continues, this therapy will become a key part of cancer care, giving patients powerful tools to fight their disease.
Integrative and Personalized Cancer Care
Integrative cancer treatment combines different methods, natural, holistic, and conventional, for a complete healing plan. It pairs intratumoral immunotherapy and intratumoral ablation with other treatments. This offers patients a more complete way to fight cancer.
Combining Intratumoral Therapy with Other Modalities
Integrative cancer care provides a multimodal, stacking, approach that mixes intratumoral therapy and ablation with chemotherapy and radiation. This stacking makes treatments more effective and improves patient results. It targets tumors and boosts the immune system, fighting cancer well, preserving the immune system, and healing the body simultaneously.
The Role of Precision Medicine in Optimizing Outcomes
Precision cancer care uses multiomic data to tailor treatments. Multiomics can be categorized into:
- Genomics
- Epigenomics
- Transcriptomics
- Proteomics
- Metabolomics
- Immunomodulomics
- Hormonomics
- Microbiomics
- Lipidomics
- Glycomics
- Exposomics
- Senolytic-omics
I jokingly add, whateveromics. These collective fields of study ensures patients get the precise therapies for their specific cancer. This approach leads to better results and fewer side effects, thanks to data-driven research.
Supporting Immune Health Alongside Conventional Treatments
Personalized oncological therapies boost the immune system while fighting cancer. Beyond intratumoral ablation and immunotherapy, immune system support can be found in diet changes, stress reduction, repurposed medications, other integrative intravenous therapies, i.e., IV vitamin C, IV artesunate, IV curcumin…, natural therapies, ayurvedic medicine, traditional chinese medicine, and supplements. These strategies help the body fight cancer better, working with conventional treatments for better health.
| Treatment Approach | Benefits | Integration with Intratumoral Therapy |
| Full-dose Chemotherapy | Kills rapidly dividing cells | Suppresses immune response triggered by intratumoral treatment |
| Low-dose Metronomic Chemotherapy | Inhibits angiogenesis and immunomodulatory | Modulates and supports immune response triggered by intratumoral treatment |
| Radiation | Targets specific tumor sites | Can increase tumor antigen release for improved immune recognition |
| Systemic Immunotherapy | Boosts overall immune function | Amplifies local and systemic effects of intratumoral therapy |
Research and Future Directions
The field of cancer immunology is moving fast. Immunotherapy research is leading to new treatments. Scientists are working on personalized cancer therapy to change patient care.
Advances in Tumor Microenvironment Targeting
Researchers are finding new ways to change the tumor microenvironment from pro-tumor to anti-tumor. Researchers aim to improve immune cells infiltration into tumors which should improve therapy effectiveness.
Emerging Therapies in Localized Immunotherapy
New treatments are being tested in pre-clinical and clinical trials. These include targeted nanoparticles and gene-editing. More areas of research are needed in the areas of integrative intratumoral immunotherapy, i.e., mistletoe, vitamin C, ivermectin, curcumin. The goal is to deliver immune-activating agents right to tumors, reducing side effects.
The Potential for Long-Term Remission
Combining different immunotherapy approaches might lead to long-term remissions. These therapies target the immune system in different ways. This could mean better tumor control and survival rates.
| Research Area | Potential Impact | Current Stage |
| Tumor Microenvironment Modulation | Enhanced immune cell activity | Early pre-clinical and clinical trials |
| Nanoparticle Delivery Systems | Precise tumor targeting | Preclinical studies |
| Combination Immunotherapies | Improved long-term outcomes | Phase II/III trials |
As research moves forward, the future of cancer treatment looks bright. Immunotherapy and personalized approaches are bringing us closer to controlling and possibly eradicating cancer.
Taking the Next Step Toward Intratumoral Therapy
Intratumoral therapy is a new hope in cancer treatment. It offers personalized medicine and local therapy options. This approach is a beacon of hope for many with cancer.
How to Discuss These Options with Your Oncologist
Talking to your oncologist about intratumoral therapy is key. Make a list of questions about its benefits and risks for you. Ask how it may fit your current treatment and ask about clinical trials coming near you soon.
Empowering Yourself with Knowledge and Resources
Start by learning about immunotherapy. Read medical journals, go to seminars, and join patient groups. Knowing the science helps you make better choices for your care.
Exploring Integrative Oncology Options
Integrative oncology mixes conventional treatments with integrative therapies. Talk to your team about adding intratumoral therapy to your care.
Intratumoral immunotherapy is transforming cancer care, offering hope through precision-targeted treatments. But true integrative medicine goes beyond a single approach. At Pre-Scribed, we explore the full spectrum of holistic and metabolic therapies, including repurposed medications, IV nutrition, and immune-enhancing strategies to give patients the best possible outcomes. Staying informed is key to making empowered decisions.
That’s why we created the Pre-Scribed Podcast, a space where cutting-edge research meets real-world application. Join the conversation as we break down the latest in integrative cancer care, interview experts, and share insights that could change the way you approach healing. Whether you’re navigating a diagnosis or seeking ways to optimize your health, you won’t want to miss this.
👉 Listen Now: Pre-Scribed Podcast
References
-
● Sheth RA, Wehrenberg-Klee E, Patel SP, Brock KK, Fotiadis N, de Baère T. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions. Radiology. 2024 Jul;312(1):e232654. doi: 10.1148/radiol.232654.
● Biologic drug-device combination immunotherapy for metastatic prostate cancer patients. MedicalXpress. medicalxpress.com/news/2024-04-biologic-drug-device-combination-immunotherapy.html. Published April 8, 2024. Accessed July 2, 2024.
● Schroeder, B. (2023, November 30). Immune action at a distance. MIT News | Massachusetts Institute of Technology. https://news.mit.edu/2023/immune-action-distance-1130
● Update on current and new potential immunotherapies in breast cancer, from bench to bedside. Frontiers in Oncology. frontiersin.org/articles/10.3389/fonc.2024.01234/full. Published 2024. Accessed July 2, 2024.
● Zhang, H., Xue, J., Gao, R., Wang, D., Liu, Y., & Xu, H. (2023). Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. Journal of Hematology & Oncology. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01307-2
●
Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer. 2021 Feb 4;20(1):27. doi: 10.1186/s12943-021-01317-7.
● Cavalcanti, I. D. L., & Soares, J. C. S. (2023). Advances in cancer treatment: From systemic chemotherapy to targeted therapy. Springer. https://link.springer.com/book/10.1007/978-3-030-68334-4 .
● Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Clin Cancer Res. 2020 Nov 1;26(21):5557-5566. doi: 10.1158/1078-0432.CCR-19-2300.
● Hong WX, Haebe S, Lee AS, Westphalen CB, Norton JA, Jiang W, Levy R. Intratumoral Immunotherapy for Early-stage Solid Tumors. Clin Cancer Res. 2020 Jul 1;26(13):3091-3099. doi: 10.1158/1078-0432.CCR-19-3642.
● Shyr CR, Liu LC, Chien HS, Huang CP. Immunotherapeutic Agents for Intratumoral Immunotherapy. Vaccines (Basel). 2023 Nov 14;11(11):1717. doi: 10.3390/vaccines11111717.
● Ghosn M, Tselikas L, Champiat S, Deschamps F, Bonnet B, Carre É, Testan M, Danlos FX, Farhane S, Susini S, Suzzoni S, Ammari S, Marabelle A, De Baere T. Intratumoral Immunotherapy: Is It Ready for Prime Time? Curr Oncol Rep. 2023 Aug;25(8):857-867. doi: 10.1007/s11912-023-01422-4.
● Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116.
● Regmi, M., Wang, Y., Liu, W. et al. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review. J Exp Clin Cancer Res 43, 47 (2024). https://doi.org/10.1186/s13046-024-02973-5- ● Das, S., Johnson, D.B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. j. immunotherapy cancer 7, 306 (2019). https://doi.org/10.1186/s40425-019-0805-8